Buyback Announcements and News

9/6/2024

Tonix Pharmaceuticals board approves share repurchase program of up to $10M - 8-K ($0.14, 0.00)

• On 6-Sep-24, Tonix Pharmaceuticals Holding Corp.'s board approved a share repurchase program pursuant to which the company may repurchase up to $10.0M in value of its outstanding common stock, par value, $0.001 per share, from time to time on the open market and in privately negotiated transactions

9/6/2024

Shopify's CEO establishes Automatic Securities Disposition Plan ($67.01, 0.00)

• The ASDP provides for the sale of an aggregate of up to 2.564M Class A Shares and will terminate no later than 31-Dec-25.

9/6/2024

Angel Oak Mortgage REIT CFO Brandon Filson discloses sale of ~23K shares ($10.93, 0.00)

• Filson beneficially owns ~76K shares of common stock following the transaction.

9/6/2024

Omega Healthcare Investors COO Daniel Booth discloses selling 25,000 shares of ($39.60, 0.00)

• Booth beneficially owns 156,725 shares following the transaction.

9/6/2024

Prospect Capital CEO John Barry discloses buy 750K shares ($5.27, 0.00)

• Barry beneficially owns 69.8M shares directly and 317.2M shares indirectly via spouse following the transaction.

9/6/2024

Insider transaction: BJ's Restaurants Interim CEO C Richmond discloses purchase of 2.5K shares - Form 4 ($29.17, -0.48)

• Richmond beneficially owns 32.4K shares of common stock following the transaction.

9/6/2024

Paltalk trading higher; CEO, President, COO, & Chairman Jason Katz discloses purchase of 25K shares - Form 4 (pre-open) ($2.72, 0.00)

• Katz beneficially owns 650.9K shares of common stock directly following the transaction; also discloses an additional 201.3K shares held by spouse.
• PALT shares are trading +13.3% higher intraday following the pre-open filing.

9/6/2024

Gyre Therapeutics Chairman Ying Luo discloses 8.5% stake vs prior 3.3% - 13D ($11.82, 0.00)

• StreetAccount notes that the language in the filing appears boilerplate.
• Luo had previously disclosed a 3.3% stake in a 14-Aug dated Form 4 filing.

9/6/2024

Brady reports Q4 EPS $1.19 ex-items vs FactSet $1.11 [3 est, $1.10-1.11]; authorizes additional $100M of shares for repurchase ($71.81, 0.00)

• Reports Q4:
  • Revenue $343.4M vs FactSet $351.7M [3 est, $350.3-353.2M]
    • organic sales growth +1.6%
• FY Guidance (Jul 2025):
  • EPS $4.40-4.70 ex-items vs FactSet $4.42 [3 est, $4.35-4.46]
  • Included in FY25 guidance are a full-year income tax rate of ~20% and depreciation and amortization expense ranging from $38M to $40M.
  • Capital expenditures are expected to approximate $35M.
• Authorizes additional $100M of shares for repurchase:
  • On 4-Sep-24, Brady's board authorized an additional $100M of Class A Nonvoting common stock for repurchase under the company's share buyback program.
  • The share buyback program may be implemented from time to time in the open market or in privately negotiated transactions and has no expiration date.

9/6/2024

Insider transaction: Bright Green CFO Saleem Elmasri discloses sale of 399K shares - Form 4 ($0.20, 0.00)

• Elmasri beneficially owns 1.2M shares of common stock following the transaction.